---
title: "Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293617770.md"
description: "China's NMPA approved Hengrui Pharma's camrelizumab and famitinib combination as a first-line treatment for PD-L1-positive recurrent or metastatic cervical cancer. This approval upgrades the regimen from second-line to first-line use, based on Phase III trial results showing a median overall survival of 35.8 months compared to 23.6 months with chemotherapy."
datetime: "2026-07-23T12:32:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293617770.md)
  - [en](https://longbridge.com/en/news/293617770.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293617770.md)
generator: "portal-rs"
---

# Hengrui Pharma wins China approval for camrelizumab-famitinib combo as 1L cervical cancer treatment

-   China’s NMPA cleared camrelizumab injection with famitinib malate for first-line recurrent or metastatic cervical cancer in PD-L1-positive patients. \* The decision upgrades the regimen from second-line to first-line use in advanced cervical cancer. \* Approval follows a phase III trial showing median OS of 35.8 months vs 23.6 months on chemotherapy in the PD-L1-positive subgroup (HR 0.634). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260723-12254653), on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares](https://longbridge.com/en/news/296370263.md)
- [Hengrui Wins NMPA Nod to Move Cervical Cancer Combo to First-Line Use](https://longbridge.com/en/news/293620453.md)
- [2 GLP-1 Stocks That Could Double Your Money by 2031](https://longbridge.com/en/news/296030914.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**